Distinguished US researcher appointed Director of Research at the Royal College of Surgeons in Ireland


Distinguished US researcher Professor Raymond Stallings has been appointed Director of Research at the Royal College of Surgeons in Ireland (RCSI). An internationally recognised leader in the area of cancer genomics, Professor Stallings has held faculty and scientific leadership positions at a number of major research centres, hospitals and universities in Ireland and the United States, including the University of Texas Health Science Centre at San Antonio, University College Dublin, Our Lady’s Children’s Hospital, Dublin, the University of Pittsburgh, the University of California and the University of Texas M.D. Anderson Cancer Centre in Houston.

 

 

 He takes up his new appointment this month following his previous position as Chair of Cancer Genetics at RCSI, which he had held since 2007.

An author and co-author of over 150 journal articles, books and book chapters, Professor Stallings is the recipient of many major peer-reviewed grant awards from national and international agencies. His current research is focused on the development of novel therapeutic approaches for the treatment of the childhood cancer neuroblastoma.

 

Professor Cathal Kelly, Chief Executive, RCSI said: “I am delighted to welcome Professor Stallings as Director of Research at RCSI.  At a time when research funding is under challenge nationally, his internationally renowned expertise in cancer genetics and ambitious vision for research at RCSI, will allow the College to build on the success of RCSI research to date and maximise the potential of our strategic partnerships to grow the College’s reputation as a centre for research excellence.”

 

Professor Raymond Stallings said: “I am honoured to take up the post of Director of Research at RCSI and to further increase the College’s standing as an internationally renowned world-class research centre. RCSI already has an outstanding base of scientists, clinicians and clinician-scientists and I believe that we can build upon this invaluable resource in many ways to further develop multi-disciplinary-teams to improve human health by tackling pressing issues for diagnosing and treating many human diseases, as well as by developing innovative solutions for many important health related issues.”

 

RCSI successes in the past year include €10.4million in research funding and the launch of two spin-off companies: i360medical, a healthcare solutions and medical device innovation company, and SurgaColl Technologies, a tissue regeneration technology company.

 

“RCSI scientists have been highly successful in using local and national grants as leverage to secure major international funding from EU andUSAsources, which in turn has contributed to employment inIreland; I wish this to continue and grow. Additionally, RCSI has already done much in terms of the commercialisation of research, with spin off companies creating high quality employment opportunities that are so vital to the country’s economic recovery.” 

 

Research at RCSI greatly enhances the educational activities of the College and Professor Stallings aims to build and expand on a number of successful programmes where research and education intersect, including Structured PhD Programmes, MSc and MD opportunities and a Research Summer School for undergraduates. 

 

“As an international organisation with a presence in the Middle andFar East, global health promotion is central to our vision. Also, with a highly multicultural campus in Dublin, RCSI is in a unique position to conduct research on medical education, an area in which I hope to develop and expand in the coming years to complement our biomedical and clinical research programmes,” Professor Stallings concluded.

 

ENDS

 

Communications Department

Royal College of Surgeons in Ireland 

123 St Stephen's Green

Dublin 2

Ireland

 

Phone + 353 1 402 2218 / 8610

Fax + 353 1 402 2458

Email: communications@rcsi.ie